Abstracts tagged "Lupus nephritis"

Abstract Number: 0068 • ACR Convergence 2022
Differential Diagnostic Coding Patterns and Associated Sociodemographic Factors in Childhood-Onset Lupus Nephritis
Emily Smitherman¹, Rouba Chahine¹, Aimee Hersh² and Jeffrey Curtis³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Utah, Salt Lake City, UT, ³University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Disparities in long-term kidney outcomes have been documented in patients with childhood-onset systemic lupus erythematosus (cSLE) complicated by lupus nephritis (LN). However, there remains…
Abstract Number: 0514 • ACR Convergence 2022
Renal Response Outcomes of North American Youth with Proliferative Lupus Nephritis Treated with the EuroLupus versus NIH Cyclophosphamide Dosing Regimen
Christine Wang¹, Rebecca Sadun², Wenru Zhou³, Kristen Miller³, Claire Palmer³, Stacy P Ardoin⁴, Christine Bacha⁵, Emily Hause⁶, Joyce Hui-Yuen⁷, Nicole Ling⁸, Maria Pereira⁹, Meredith Riebschleger¹⁰, Kelly Rouster-Stevens¹¹, Aliese Sarkissian¹², Julia Shalen¹³, William Soulsby¹⁴, Marinka Twilt¹⁵, Eveline Wu¹⁶, Laura Lewandowski¹⁷, Scott Wenderfer¹⁸ and Jennifer Cooper¹⁹, ¹Children's Hospital of Colorado/University of Colorado, Denver, CO, ²Duke University, Durham, NC, ³University of Colorado School of Medicine, Aurora, CO, ⁴Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶University of Minnesota, Minneapolis, MN, ⁷Cohen Children’s Medical Center, Hofstra-Northwell School of Medicine, Feinstein Institutes for Medical Research, Queens, NY, ⁸UCSF, San Francisco, CA, ⁹Baylor College of Medicine, Houston, TX, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Division of Pediatric Rheumatology, Department of Pediatrics, Emory University School of Medicine; Children’s Healthcare of Atlanta, Atlanta, GA, ¹²University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴University of California, San Francisco, San Francisco, CA, ¹⁵Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹⁶University of North Carolina, Chapel Hill, NC, ¹⁷NIAMS, NIH, Bethesda, MD, ¹⁸British Columbia Children's Hospital, Vancouver, BC, Canada, ¹⁹Children's Hospital of Colorado/University of Colorado, Aurora, CO
Background/Purpose: There have been no published studies comparing renal outcomes of youth with proliferative lupus nephritis (LN) treated with the lower-dose EuroLupus (EL) cyclophosphamide (CYC)…
Abstract Number: 0655 • ACR Convergence 2022
Proteomic Analysis of Histological Lesions Lupus Nephritis Identifies an Inflammatory Signature of Fibrous Crescents
Alessandra Ida Celia¹, Jeffery Hodgin², Avi Rosenberg³, Laurence S Magder⁴, Jill Buyon⁵, Betty Diamond⁶, Judith James⁷, William Apruzzese⁸, Paride Fenaroli⁹, Derek Fine¹, Jose Monroy-Trujillo¹, Mohamed G. Atta¹, Peter izmirly¹⁰, Michael Belmont⁵, Anne Davidson⁶, Daniel W. Goldman¹¹, the Accelerating Medicines Partnership (AMP) RA/SLE¹², Michelle Petri¹¹ and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²University of Michigan, Ann Arbor, MI, ³Johns Hopkins University, Ballwin, MO, ⁴University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, ⁵NYU Grossman School of Medicine, New York, NY, ⁶Feinstein Institutes for Medical Research, Manhasset, NY, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Brigham and Women's Hospital, Boston, MA, ⁹Università degli Studi di Parma, Parma, Emilia-Romagna, Italy, ¹⁰NYU Long Island School of Medicine, New York, NY, ¹¹Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹²Multiple Insitutions
Background/Purpose: We employed urine proteomics to define the molecular signatures associated with the histological features quantified by the NIH activity and chronicity indices. Methods: Glomerular…
Abstract Number: 1440 • ACR Convergence 2022
Interrelation of T-cell Cytokines and Autoantibodies in Lupus Nephritis: A Cross-sectional Study
Fatima Alduraibi¹, Kathryn Sullivan¹, Winn Walter Chatham², Hui-Chen Hsu¹ and John Mountz¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Clinical Immunology and Rheumatology, Birmingham, AL
Background/Purpose: To determine if different classes of lupus nephritis (LN) are correlated with specific circulating autoantibodies (autoAbs) and T-helper cell cytokines and other manifestations of…
Abstract Number: 1719 • ACR Convergence 2022
NLRP12 Deficiency Mice Present Severer Lupus Nephritis in a Pristane-Induced Lupus Like Model
Yen Po Tsao¹, Fang-Yu Tseng², Ming-Han Chen³ and SZUTING CHEN², ¹Taipei Veterans General Hospital, Taipei, Taiwan, ²National Yang Ming Chao Tung University, Taipei, Taiwan, ³Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan
Background/Purpose: Systemic lupus erythematous (SLE) is a systemic autoimmune disease that interferon (IFN) signature involved in the progress. NLRP12 (NOD-like receptor family (NLR) pyrin domain…
Abstract Number: 0356 • ACR Convergence 2021
The Role of Neutrophils in the Clinical Severity of Lupus Nephritis Patients with Concurrent Skin Disease
Lais Osmani, Sicong Shan, Zoe Chafouleas, Jason Pettus and Sladjana Skopelja-Gardner, Dartmouth Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Skin disease affects >80% of lupus patients and has been linked to lupus nephritis (LN) flares. We recently found that skin inflammation caused by…
Abstract Number: 1279 • ACR Convergence 2021
Impact of Active Lupus Nephritis in Patient-Reported Outcomes from a Latin American, Multicenter Lupus Cohort
Romina Nieto¹, Eduardo Ferreira Borba², Eugenia Settecasse³, Diana Fernandez-Avila⁴, Laura Maurelli⁵, Carla Gobbi⁶, Verónica Saurit⁷, Fernando Arizpe⁸, Julieta Daniele⁹, Maria Constanza Bertolaccini¹⁰, Eduardo Kerzberg¹¹, María de los Ángeles Gargiulo¹², Anabella Rodriguez¹³, Ana Carolina Londe¹⁴, Vitalina Sousa Barbosa¹⁵, Andrese Aline Gasparin¹⁶, Carolina Albanez A Cunha Andrade¹⁷, Luciana Parente Costa Seguro¹⁸, Lucas Victoria de Oliveira Martins¹⁹, Oscar Neira²⁰, Carolina Llanos²¹, Loreto Massardo²², Antonio Iglesias²³, Ivana Nieto Aristizábal²⁴, Gloria Vasquez²⁵, Paul Mendez-Patarroyo²⁶, Lizeth de la Hoz Rueda²³, José Martínez Pérez²⁷, Reyna Sánchez Briones²⁸, Mario Pérez Cristóbal²⁹, Eduardo Martin-Nares³⁰, Yaneli Juárez-Vicuña³¹, Yelitza Gonzalez Bello³², Jorge González García³³, Dionicio Galarza-Delgado³⁴, Marcos Vázquez³⁵, Patricia Langjarh³⁵, Magaly Alva Linares³⁶, Cristina Reategui-Sokolova³⁷, Armando Calvo Quirós³⁸, Edral Rodriguez³⁹, Ricardo Robaina⁴⁰, Martín Rebella⁴¹, Graciela Alarcn⁴², Ashley Orillion⁴³, Chetan Karyekar⁴⁴, Federico Zazzetti⁴⁵ and Guillermo Pons-Estel⁴⁶, ¹Hospital Provincial de Rosario, Rosario, Argentina, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ³Instituto de Investigaciones Teóricas y Aplicadas. Facultad de Ciencias Económicas y Estadistica. Universidad Nacional de Rosario, Rosario, Argentina, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Hospital Italiano de Córdoba, Córdoba, Argentina, ⁶Hospital Córdoba, Córdoba, Argentina, ⁷Hospital Privado Universitario de Córdoba, Córdoba, ⁸Hospital HIGA San Martín, La Plata, Argentina, ⁹Sanatorio Británico, Rosario, Argentina, ¹⁰Hospital Padilla, San Miguel de Tucumán, Argentina, ¹¹Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, ¹²Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, ¹³CEMIC, Buenos Aires, Argentina, ¹⁴Universidade Estadual de Campinas, Faculdade de Ciencias Médicas, São Paulo, Brazil, ¹⁵Hospital das Clinicas, Univerisad Federal de Goias, Goias, Brazil, ¹⁶Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ¹⁷Universidad Federal de Pernambuco, Recife, Brazil, ¹⁸Hospital Das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil, ¹⁹Universidad Federal São Paulo, São Paulo, Brazil, ²⁰Hospital del Salvador, Santiago, Chile, ²¹Facultad de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile, ²²Universidad San Sebastián, Santiago, Chile, ²³Clínica de la Costa Ltda., Barranquilla, Colombia, ²⁴Fundación Valle del Lili, Cali, Colombia, ²⁵Division of rheumatology, Universidad de Antioquia, Medellin, Colombia, ²⁶Reumavance Group, Rheumatology section, Department of Internal Medicine, Fundación Santa Fe de Bogotá University Hospital; Department of Internal Medicine, School of Medicine, Universidad de Los Andes, Bogota, Colombia, ²⁷Hospital Luis Vernaza, Guayaquil, Ecuador, ²⁸Centro Médico La Raza, Ciudad de México, Mexico, ²⁹Centro Médico Nacional Siglo XXI, Ciudad de México, Mexico, ³⁰Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³¹Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, ³²Centro de Estudios de investigación Básica y Clínica S.C, Guadalajara, Mexico, ³³Hospital Central Dr. Ignacio Morones Prieto, San Luís Potosí, Mexico, ³⁴Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico, ³⁵Hospital de Clínicas I, Asunción, Paraguay, ³⁶Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ³⁷Hospital Guillermo Almenara Irigoyen, Lima, Peru, ³⁸Hospital Cayetano Heredia, Lima, Peru, ³⁹Hospital Docente Padre Billini, Santo Domingo, Dominican Republic, ⁴⁰Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, ⁴¹Unidad de Enfermedades Autoinmunes Sistémicas de Médica Uruguay Corporación de Asistencia Médica (MUCAM); Unidad de Enfermedades Autoinmunes Sistémicas del Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, ⁴²University of Alabama at Birmingham, Birmingham, AL, ⁴³Global Commercial Strategic Organisation, Johnson and Johnson, Horsham, PA, ⁴⁴Janssen R&D, Spring House, PA, ⁴⁵Medical Affairs, Jan-Cil Argentina, Buenos Aires, Argentina, ⁴⁶Grupo Oroño. Centro Regional de Enfermedades Autoinmunes y Reumaticas (GO-CREAR), Rosario, Argentina
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple and heterogeneous clinical manifestations that may negatively affect these patients’ quality of life…
Abstract Number: 1736 • ACR Convergence 2021
Treatment of Lupus Nephritis with Belimumab Is Associated with Reduction in Urinary CD23
Emma Weeding¹, Andrea Fava², Chandra Mohan³, Daniel Goldman⁴ and Michelle Petri⁴, ¹Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³University of Houston, Houston, TX, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Urine proteomic approaches have shown promise in identifying dynamic biological pathways in lupus nephritis (LN) which are not captured on renal histopathology or by…
Abstract Number: 0454 • ACR Convergence 2021
Lupus Nephritis Mortality in the United States, 1999-2019: Profound Disparities by Race/Ethnicity and Place of Residence and a Recent Worsening Trend
Eric Yen¹, Snehin Rajkumar¹, Rohan Sharma¹ and Ram Singh², ¹University of California Los Angeles, Los Angeles, CA, ²University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Mortality from SLE has improved over the last two decades, but remains disproportionately high relative to general population mortality. Lupus nephritis (LN) occurs in…
Abstract Number: 1280 • ACR Convergence 2021
Generation of Evidence Supporting the Content Validity of SF-36, Lupus-Qol, and FACIT-Fatigue, and Newly Developed Patient-reported Outcome (PRO) Symptom Items to Address Conceptual Gaps for Use in Patient with Lupus Nephritis
Rebecca Hall¹, Nicola Williamson¹, Melissa Barclay¹, Anna Roberts¹, Adam Gater¹, Chloe Tolley¹, Helena Bradley¹, Amy Ward¹, Patricia Delong², Elizabeth Hsia³, Qing Zuraw⁴, Zahi Touma⁵, Vibeke Strand⁶ and Pamela Berry², ¹Adelphi Values Ltd, Bollington, United Kingdom, ²Janssen Global Services, LLC, Horsham, PA, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen R&D, Wayne, PA, ⁵University of Toronto, Mississauga, ON, Canada, ⁶Stanford University School of Medicine, Portola Valley, CA
Background/Purpose: Lupus nephritis (LN) is an autoimmune disease characterized by inflammation of the kidneys, a severe manifestation of systemic lupus erythematosus (SLE) that occurs in…
Abstract Number: 1737 • ACR Convergence 2021
Reduction in Urinary CD163 Is Associated with Treatment Response in the Belimumab Lupus Nephritis Trial
Emma Weeding¹, Andrea Fava², Chandra Mohan³, Daniel Goldman⁴ and Michelle Petri⁴, ¹Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³University of Houston, Houston, TX, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Urinary CD163 is a macrophage marker which correlates with histological activity index and response to treatment in lupus nephritis (LN), as evidenced by urine…
Abstract Number: 0470 • ACR Convergence 2021
Inhibition of Toll-Like Receptor 7 (TLR7) with the Potent and Selective Inhibitor of Human TLR7 and TLR8 BMS-986256 Provides Robust Efficacy in Murine Lupus Models, Reversing Established Disease
Shailesh Dudhgaonkar¹, Anjuman Rudra¹, Sourabh Ranade¹, Siva Subramani¹, Jignesh Nagar¹, Preethi Karunanithi¹, Priyadeep Bhutani¹, Vishwanath Kurawattimath¹, Rosemary Zhang², Hongchen Qiu², ALARIC DYCKMAN² and Gary Schieven², ¹Biocon Bristol Myers Squibb Research Center, Bangalore, India, ²Bristol Myers Squibb, Lawrenceville, NJ
Background/Purpose: TLR7, a member of the Toll-Like Receptor family, recognizes ssRNA and is primarily expressed in plasmacytoid dendritic cells and B cells. TLR7 has been…
Abstract Number: 1284 • ACR Convergence 2021
One Third of Lupus Nephritis Patients Classified as Complete Responders Continue to Accrue Progressive Renal Damage Despite Resolution of Proteinuria
Emma Weeding¹, Andrea Fava², Daniel Goldman³ and Michelle Petri³, ¹Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Up to 40% of individuals with lupus nephritis (LN) develop chronic kidney disease (CKD). Biopsy studies have revealed that patients with SLE can have…
Abstract Number: 1744 • ACR Convergence 2021
Improvement of Renal and Non-Renal SLE Outcome Measures on Sirolimus Therapy – a 21-year Follow-up Study of 73 Patients
Paramarajan Piranavan¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²State University of New York, Syracuse, NY
Background/Purpose: The clinical heterogeneity of the SLE makes it often challenging for the treating clinician and also remains one of the many reasons behind failed…
Abstract Number: 0472 • ACR Convergence 2021
An Atlas of Human and Mouse Intrarenal Immune Cells in Lupus Nephritis Reveals Homologous Immune Populations Across Common Mouse Strains and Species
Paul Hoover¹, Michael Peters², David Lieb², Runci Wang³, Garett Dunlap⁴, Deepak Rao¹, Nir Hacohen² and Anne Davidson⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Broad Institute, Cambridge, MA, ³Brigham and Women’s Hospital, Boston, MA, ⁴Harvard University, Somerville, MA, ⁵Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: We discovered 21 immune cell-types in lupus nephritis kidney biopsies as part of the Accelerating Medicines Partnership (AMP) consortium. These immune cells are the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.